RxDoctor Payments Data

Marie-France Poulin

Interventional Cardiology · Boston, MANPI 1780815266

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $44,505 of the $66,533 with a category attached, or 66.9%. 13 manufacturers reported payments, led by Edwards Lifesciences at 39.7% of the total. 2025 is the largest year on record at $39,878, 8.1 times the $4,931 reported in 2019.

$66,533in general payments, 2019–2025

Across 154 payments — averaging $432.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$26K
  • Cordis US CORP.$12K
  • Medtronic$11K
  • Medical Device Business Services, Inc.$8K
  • Abiomed$4K
  • Abbott$4K
  • plus $1K from 7 others
$381,056in research payments, 2019–2025

Across 55 payments — averaging $6928.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$219K
  • M.a. Med Alliance S.A.$156K
  • Daiichi Sankyo Inc.$6K

What the payments were for

  • Consulting fees$44,50567%
  • Speaking & faculty fees$5,0448%
  • Travel & lodging$9,73015%
  • Food & beverage$7,25311%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$66,533 in reported general payments places this provider in the 85th percentile of 128 interventional cardiology providers in Massachusetts.

See all interventional cardiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$135,302
Medicare patients
472
Services billed
813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban20$16,382
Metoprolol Succinate14$324

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →